A next generation
gene therapy company

At ViGeneron, we are dedicated to developing innovative gene therapies
to treat ophthalmic diseases with high unmet medical need.
Our two novel gene therapy platforms are designed to overcome the limitations of existing adeno-associated virus (AAV)-based gene therapies and enable the delivery of larger genes as well as superior transduction and less invasive administration routes.

With our next generation vector platforms, we are creating an in-house pipeline in ophthalmic gene therapy. Also, we are interested in partnerships with biopharmaceutical players in other disease areas.

The novel techniques we develop are based on well-founded scientific results. Together with leading biopharmaceutical partners, we are also addressing other exciting opportunities beyond ophthalmology, potentially in the fields of neuroscience, cardiovascular and liver.